[{"id":"dd849209-d63d-4be8-8b30-8630c3f63b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT05874414","created_at":"2023-05-24T18:06:43.955Z","updated_at":"2024-07-02T16:35:05.935Z","phase":"Phase 1/2","brief_title":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma","source_id_and_acronym":"NCT05874414","lead_sponsor":"Genfit","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • ezurpimtrostat (GNS561)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/21/2023","start_date":" 08/21/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-03"},{"id":"c3005ef7-71ae-4128-b1ae-282cc4e68429","acronym":"IMMUNONCOVID","url":"https://clinicaltrials.gov/study/NCT04333914","created_at":"2021-01-18T20:59:05.040Z","updated_at":"2024-07-02T16:36:03.152Z","phase":"Phase 2","brief_title":"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","source_id_and_acronym":"NCT04333914 - IMMUNONCOVID","lead_sponsor":"Centre Leon Berard","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e avdoralimab (IPH5401) • ezurpimtrostat (GNS561) • monalizumab (IPH2201)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/15/2020","start_date":" 04/15/2020","primary_txt":" Primary completion: 07/06/2021","primary_completion_date":" 07/06/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-30"}]